From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
MCA is a coumarin derivative. MCA quantitates platelet-activatingfactor by high-performance liquid chromatography with fluorescent detection. MCA can modify FRET peptide substrates for analyzing protease activities .
P11 is a selective inhibitor of platelet-activatingfactor acetylhydrolases (PAFAHs) 1b2 and 1b3 that impairs cancer cell survival. P11 exhibits IC50 values of ~40 and 900 nM for PAFAH1b2 and 1b3, respectively .
Modipafant (UK-80067), the (+)-enantiomer of UK-74505, is a potent, orally active, and selective platelet-activatingfactor(PAF) antagonist. Modipafant exhibits approximately double the intrinsic potency of UK-74505 .
Acopafant (Dacopafant; RP 55778) is a potent platelet-activatingfactor antagonist. Acopafant inhibits the induction of human immunodeficiency virus (HIV) expression in chronically infected cells. Acopafant has the potential for the research of HIV infection .
Aristolactam A IIIa (Sch 546909) is an aristolactam-type alkaloid that can be isolated from Glycosmis chlorosperma. Aristolactam A IIIa is a DYRK1A Inhibitor. Aristolactam A IIIa inhibits platelet aggregation induced by arachidonic acid (AA), collagen and platelet-activatingfactor (PAF). Aristolactam A IIIa has strong cytotoxic effect on HeLa cells .
C16-PAF (PAF (C16)), a phospholipid mediator, is a platelet-activatingfactor and ligand for PAF G-protein-coupled receptor (PAFR). C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR. C16-PAF is a potent MAPK and MEK/ERK activator. C16-PAF induces increased vascular permeability .
Aglafoline inhibits in a selective and concentration-dependent manner the aggregation and ATP release reaction induced in washed rabbit platelets by PAF (platelet-activatingfactor).
Pinusolide is a known platelet-activatingfactor (PAF) receptor binding antagonist. Pinusolide not only decreases the proliferation activity of tumor cells but specifically induces apoptosis .
Dersalazine (UR-12746 free base) is an inhibitor of platelet-activatingfactor, exhibiting intestinal anti-inflammatory activity and potential efficacy in treating ulcerative colitis.
Spiradine F is a main alkaloidal component of spiraea japonioa L. fil. Spiradine F derivative can inhibit platelet-activatingfactor (PAF)-induced platelet aggregation .
Dersalazine (sodium) is a platelet-activatingfactor (PAF) antagonist. Dersalazine (sodium) can exert intestinal anti-inflammatory activity in rodent colitis models by downregulating IL-17 expression .
Carbamyl-PAF is an analog and agonist of platelet-activatingfactor (PAF). Carbamyl-PAF is not significantly metabolized by Raji lymphoblasts at 37°C, making it a useful tool for inflammation research. .
L662,025 is a specific, photolabile and irreversible Platelet-activatingfactor (PAF-receptor) antagonist, with IC50 values of 5.6 μM (platelet aggregation) and 1 μM (receptor binding), respectively .
1,6-Dihydro-4,7-epoxy-1-methoxy-3,4-methylenedioxy-6-oxo-3,8-lignan, a lignan derivative from the ethyl acetate soluble fraction of twigs of Magnolia denudate (Magnoliaceae), exhibits anti-platelet-activatingfactor (PAF) activity. PAF is a potent lipid mediator in inflammation and asthma .
(+)-Guaiacin is a compound extracted of the bark of Machilus wangchiana Chun. (Lauraceae). (+)-Guaiacin shows potent in vitro activities against the release of β-glucuronidase in rat polymorphonuclear leukocytes (PMNs) induced by platelet-activatingfactor (PAF) .
N-Acetyldesloratadine (SCH-37370) is a potent, orally active dual antagonist of platelet-activatingfactor (PAF) and histamine. N-Acetyldesloratadine inhibits PAF-induced aggregation of human platelets, with an IC50 of 0.6 µM .
Bepafant (Web2170) is a platelet-activatingfactor (PAF) antagonist that protects against anaphylactic lethality in active and passive anaphylaxis models in mice and guinea pigs in a dose-dependent manner and attenuates bronchoconstriction and blood pressure changes in anaphylaxis.
Kadsurenin B is a PAF (platelet-activatingfactor) antagonist with neuroprotective activity. Kadsurenin B has a wide range of pharmacological research potential, such as antibacterial, anti-inflammatory, neuroprotective, antioxidant, antiplatelet aggregation, cytotoxic, antiparasitic, etc .
Homoeriodictyol 7-O-β-D-glucoside is a natural platelet-activatingfactor (PAF) antagonist. Homoeriodictyol 7-O-β-D-glucoside inhibits human and rabbit platelet aggregation induced by PAF, with an IC50 of 0.8 μM .
ABT-299 is a prodrug of a platelet-activatingfactor (PAF) antagonist that exhibits significant inhibitory activity on PAF-induced β-platelet globulin release in vitro after in vivo administration in humans, an effect that may be partially attributed to the pyridine-N-oxide metabolite.
α-Bulnesene is a novel PAF receptor antagonist with the IC50 of 17.62 μM. α-Bulnesene can be isolated from Pogostemon cablin. α-Bulnesene shows inhibitory effect on platelet-activatingfactor and arachidonic acid induced rabbit platelet aggregation .
Ro 24-4736 is a potent, selective, p.o.-active platelet-activatingfactor (PAF) antagonist with a long duration of action. Ro-24-4736 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
2-O-Ethyl PAF C-16 is a homolog of PAF and a competitive ligand for PAF receptor (Platelet-activatingFactor Receptor (PAFR)). 2-O-Ethyl PAF C-16 inhibits the binding of the PAF antagonist WEB 2086 (HY-108634) to the PAF receptor with an IC50 of 21 nM .
Foropafant (SR27417) highly potent, competitive, selective and orally active antagonist of platelet-activatingfactor (PAF) receptor, with a Ki value of 57 pM for [ 3H]PAF binding, at least 5-fold lower than that of unlabeled PAF itself. Foropafant potently inhibits PAF-induced aggregation of rabbit and human platelets .
C18-PAF, octadecane PAF, is the ligand of platelet-activatingfactor and PAF G protein-coupled receptor (PAFR). C18-PAF has renovasodilator properties and antihypertensive lipid properties. C18-PAF increases renal blood flow and causes dose-dependent systemic hypotension .
CL-184005 is an antagonist for platelet-activatingfactor (PAF), that inhibits the PAF-induced platelet aggregation with IC50 of 600 nM and 510 nM, in human and rabbit platelet-rich plasma. CL-184005 protects the rats from endotoxin-induced gastrointestinal damage and hypotension. CL-184005 exhibits potential attenuating Gram-negative bacterial sepsis .
Lyso-PAF C-18 is an intermediate for the synthesis of C18-PAF (HY-130345). It has an easily substituted "Lyso-PAF" structure and is easy to purify and has high yield. C18-PAF is a ligand for platelet-activatingfactor and PAF G protein-coupled receptor (PAFR) and has renovasodilator properties and antihypertensive lipid properties .
(7-Methoxy-2-oxo-2H-chromen-4-yl)-acetic acid-d3 is the deuterium labeled MCA[1]. MCA is a coumarin derivative. MCA quantitates platelet-activatingfactor by high-performance liquid chromatography with fluorescent detection. MCA can modify FRET peptide substrates for analyzing protease activities[2][3].
R-75317 is a specific platelet-activatingfactor (PAF) antagonist. R-75317 can prevent the decline in creatinine clearance (Ccr) in a rat model of glomerulonephritis induced by the injection of antibodies extracted from rabbits against rat glomerular basement membrane (GBM) antigens, delay the onset of proteinuria, and improve glomerular hypertrophy, mesangial matrix proliferation, and interstitial fibrosis. R-75317 may be useful in the study of glomerulonephritis .
AM103 (free acid) is a selective FLAP inhibitor that can block the first step of the LT pathway, which is 5-LO activation. AM103 (free acid) can inhibit the production of LTB4 and cysteinyl leukotrienes (CysLT). AM103 (free acid) has anti-inflammatory activity in a mouse model of chronic lung inflammation and can extend the survival time of mice injected with platelet-activatingfactor. AM103 (free acid) can be used for research on respiratory diseases such as asthma .
Rocepafant (BN 50730) is a specific platelet activatingfactor (PAF) antagonist. Rocepafant can be used in rheumatoid arthritis and nervous system research .
Scandenolide is a sesquiterpene lactone that can be found in Philippines medicinal plant Mikania cordata. Scandenolide inhibits leukotriene and platelet activatingfactor synthesis in leukocytes .
Hexanolamino PAF C-16 (1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N trimethyl) hexanolamine) is a Platelet-activatingFactor Receptor (PAFR) Modulator with partial agonist activity. Hexanolamino PAF C-16 induces platelet aggregation and macrophage production but fails to increase [Ca2+]i in platelets, suggesting that PAF receptors may interact with PAF receptors through Ca 2+-dependent and -independent pathways. Related to platelet aggregation .
Ro-24-0238 is an antagonist of platelet activatingfactor (PAF) and inhibitor of thromboxane synthesis, used for lessening the inflammation and damage resulting from a local release of PAF.
Kadsurin A is a new lignan can be isolated from Piper futokadsura. Kadsurin A is a platelet activatingfactor (PAF) receptor antagonist that weakly inhibits the binding of PAF to its receptor .
CP-96486 is a potent and orally active leukotriene D4(LTD4)/platelet activatingfactor (PAF) receptor antagonist with Kis of 20 and 24 nM, respectively.
Platelet-activatingfactor (PAF) is a pro-inflammatory phospholipid mediator that is rapidly synthesized by lyso-PAF acetyltransferase (lyso-PAFAT) in response to extracellular stimuli. Two types of lyso-PAFAT have been identified: lysophosphatidylcholine acyltransferase (LPCAT)1, which is mostly expressed in the lungs, and LPCAT2, which is expressed in inflammatory cells. TSI-01 is a selective inhibitor of LPCAT2 (IC50s=0.47 versus 3.02 μM for human LPCAT2 and LPCAT1, respectively). 60 μM it is shown to suppress PAF biosynthesis in mouse peritoneal macrophages stimulated with a calcium ionophore.
C16-18:1 PC (1-O-Hexadecyl-2-oleoyl-sn-glycero-3-phosphocholine), also known as 1-O-hexadecyl-2-oleoyl-sn-glycero-3-phosphocholine (HOPC), is a member of the platelet-activatingfactor (PAF) family of glycerophospholipids and serves as a pro-inflammatory lipid mediator with diverse biological and pharmacological effects; it features a mono-ether structure with an oleoyl chain (18:1) ester-linked at the sn-2 position and a hexadecyl chain (16:0) ether-linked at the sn-1 position.
CP-96021 hydrochloride is a balanced, combined, potent and orally active leukotriene D4 (LTD4)/platelet activatingfactor (PAF) receptor antagonist with Ki values of 34 nM and 37 nM, respectively .
(Rac)-L-659989 is the racemate of L-659989 (HY-121394). L-659989 s an orally active, extremely potent, selective and competitive platelet activatingfactor (PAF) receptor antagonist .
TCV-309 is an antagonist for platelet activatingfactor (PAF). TCV-309 improves the left ventricular function during ischemia-reperfusion (77.6% recover at 1 μM), protects the cardiac function .
Epiyangambin is a competitive platelet activatingfactor receptor (PAF) antagonist that dose-dependently inhibits PAF-induced platelet aggregation. Epiyangambin also inhibits the growth of human colon cancer cells (SW480 cells) .
Rilapladib (SB 659032) is a selective Lp-PLA2 (lipoprotein-associated phospholipase A2) inhibitor with an IC50 of 230 pM . Rilapladib (SB 659032) is also a PAFR (Platelet ActivatingFactor Receptor) antagonist .
3-O-Methylquercetin tetraacetate is an antiplatelet agent. 3-O-Methylquercetin tetraacetate has potent antiplatelet effect on arachidonic acid, collagen-induced and PAF-induced platelet aggregation .
SDZ-MKS 492 (MKS 492) is a selective inhibitor of cyclic GMP-inhibited phosphodiesterase (type III PDE). SDZ-MKS 492 inhibits antigen- or platelet activatingfactor (PAF)-induced bronchoconstriction and allergic reactions in guinea pigs and rats .
Kadsurenin C (compound 1) is a neolignan that can be isolated from the aerial part of Piper kadsura with anti-inflammation activity. Kadsurenin C exhibits significant PAF (Platelet ActivatingFactor)
antagonistic activity with IC50 value of 5.1 μM .
FR 106969 (A26771E) is a platelet activatingfactor antagonist with anti-inflammatory activity. FR 106969 can be used to alleviate inflammatory responses. FR 106969 has shown potential inhibitory effects on inflammation-related diseases in studies .
(7-Methoxy-2-oxo-2H-chromen-4-yl)-acetic acid-d6 is the deuterium labeled MCA[1]. MCA is a coumarin derivative. MCA quantitates platelet-activatingfactor by high-performance liquid chromatography with fluorescent detection. MCA can modify FRET peptide substrates for analyzing protease activities[2][3]. (7-Methoxy-2-oxo-2H-chromen-4-yl)-acetic acid-d6 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Aschantin, a bisepoxylignan, can be isolated from Magnolia biondii. Aschantin has antiplasmodial, Ca 2+-antagonistic, platelet activatingfactor-antagonistic, and chemopreventive activities. Aschantin is a mTOR kinase inhibitor. Aschantin is also an inhibitor of Cytochrome P450 and UGT enzyme .
L 651142 is a weak platelet activatingfactor (PAF) receptor antagonist. L 651142 inhibits the binding of [ 3H]PAF to rabbit platelet, human platelet or human lung membranes with Kis of 0.839 μM, 1.82 μM, 3.64 μM, respectively .
CV-6209 is a potent antagonist of platelet activatingfactor (PAF). CV-6209 inhibits the PAF-induced aggregation of rabbit and human platelets, with IC50s of 75 nM and 170 nM, respectively. CV-6209 can inhibit PAF-induced hypotension in rats .
TCV-309 chloride is a potent and specific platelet activatingfactor (PAF) antagonist. TCV-309 chloride specifically inhibits PAF-induced aggregation of rabbit and human platelets, and [3H]PAF binding to rabbit platelet microsomes with IC50 values of 33 nM, 58 nM and 27 nM, respectively. TCV-309 chloride has beneficial effects in anaphylactic shock .
Ginkgolide B (BN-52021), a terpene lactone, is a potent platelet activatingfactor antagonist. Ginkgolide B protects endothelial cells via the activation of PXR from injuries induced by xeno- and endobiotics. Ginkgolide B can pass through the brain-blood barrier. Ginkgolide B has anti-oxidant, anti-inflammatory, anti-tumor, and anti-apoptotic activity. Ginkgolide B has marked neuroprotective effects against ischemia-induced impairments .
Israpafant (Y-24180) is a potent, selective and long-acting platelet activationfactor (PAF) receptor antagonist with IC50s of 0.84 nM and 3.84 nM against PAF-induced human and rabbit platelet aggregation, respectively. Israpafant stimulates both extracellular Ca 2+ influx and intracellular Ca 2+ release in prostate cancer cells. Israpafant suppresses the allergic cutaneous reactions including eosinophilia, cytokine production, edema and erythema in mice .
Lp-PLA2-IN-4 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activatingfactor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-4 has the potential for the research of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease (extracted from patent WO2021228159A1, compound 38) .
Lp-PLA2-IN-5 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activatingfactor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-5 has the potential for the research of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease (extracted from patent WO2021228159A1, compound 32) .
Lp-PLA2-IN-11 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activatingfactor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-11 has the potential for the research of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease (extracted from patent WO2014114249A1, compound E145) .
Lp-PLA2-IN-10 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activatingfactor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-10 has the potential for the research of neurodegenerative-related diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), or cardiovascular diseases including atherosclerosis (extracted from patent WO2022001881A1, compound 4) .
CP-96021 is a potent and orally available leukotriene D4 (LTD4Ki=34 μM) / platelet activatingfactor (PAFKi=37 μM) receptor antagonist. CP-96021 has antagonist capable of simultaneously targeting two different inflammatory mediators, LTD4 and PAF. CP-96021 shows high specificity for α1, α2, β, dopamine-2, adenosine 1, 5-HT1, H1, muscarine, μ opioid, and GABA receptors, all expressing IC50 values greater than 10 μM. CP-96021 can be used to study the pathogenesis of many inflammatory diseases such as asthma .
MCA is a coumarin derivative. MCA quantitates platelet-activatingfactor by high-performance liquid chromatography with fluorescent detection. MCA can modify FRET peptide substrates for analyzing protease activities .
C16-PAF (PAF (C16)), a phospholipid mediator, is a platelet-activatingfactor and ligand for PAF G-protein-coupled receptor (PAFR). C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR. C16-PAF is a potent MAPK and MEK/ERK activator. C16-PAF induces increased vascular permeability .
Aristolactam A IIIa (Sch 546909) is an aristolactam-type alkaloid that can be isolated from Glycosmis chlorosperma. Aristolactam A IIIa is a DYRK1A Inhibitor. Aristolactam A IIIa inhibits platelet aggregation induced by arachidonic acid (AA), collagen and platelet-activatingfactor (PAF). Aristolactam A IIIa has strong cytotoxic effect on HeLa cells .
Pinusolide is a known platelet-activatingfactor (PAF) receptor binding antagonist. Pinusolide not only decreases the proliferation activity of tumor cells but specifically induces apoptosis .
Spiradine F is a main alkaloidal component of spiraea japonioa L. fil. Spiradine F derivative can inhibit platelet-activatingfactor (PAF)-induced platelet aggregation .
1,6-Dihydro-4,7-epoxy-1-methoxy-3,4-methylenedioxy-6-oxo-3,8-lignan, a lignan derivative from the ethyl acetate soluble fraction of twigs of Magnolia denudate (Magnoliaceae), exhibits anti-platelet-activatingfactor (PAF) activity. PAF is a potent lipid mediator in inflammation and asthma .
(+)-Guaiacin is a compound extracted of the bark of Machilus wangchiana Chun. (Lauraceae). (+)-Guaiacin shows potent in vitro activities against the release of β-glucuronidase in rat polymorphonuclear leukocytes (PMNs) induced by platelet-activatingfactor (PAF) .
Kadsurenin B is a PAF (platelet-activatingfactor) antagonist with neuroprotective activity. Kadsurenin B has a wide range of pharmacological research potential, such as antibacterial, anti-inflammatory, neuroprotective, antioxidant, antiplatelet aggregation, cytotoxic, antiparasitic, etc .
Homoeriodictyol 7-O-β-D-glucoside is a natural platelet-activatingfactor (PAF) antagonist. Homoeriodictyol 7-O-β-D-glucoside inhibits human and rabbit platelet aggregation induced by PAF, with an IC50 of 0.8 μM .
α-Bulnesene is a novel PAF receptor antagonist with the IC50 of 17.62 μM. α-Bulnesene can be isolated from Pogostemon cablin. α-Bulnesene shows inhibitory effect on platelet-activatingfactor and arachidonic acid induced rabbit platelet aggregation .
Lyso-PAF C-18 is an intermediate for the synthesis of C18-PAF (HY-130345). It has an easily substituted "Lyso-PAF" structure and is easy to purify and has high yield. C18-PAF is a ligand for platelet-activatingfactor and PAF G protein-coupled receptor (PAFR) and has renovasodilator properties and antihypertensive lipid properties .
Scandenolide is a sesquiterpene lactone that can be found in Philippines medicinal plant Mikania cordata. Scandenolide inhibits leukotriene and platelet activatingfactor synthesis in leukocytes .
Kadsurin A is a new lignan can be isolated from Piper futokadsura. Kadsurin A is a platelet activatingfactor (PAF) receptor antagonist that weakly inhibits the binding of PAF to its receptor .
Epiyangambin is a competitive platelet activatingfactor receptor (PAF) antagonist that dose-dependently inhibits PAF-induced platelet aggregation. Epiyangambin also inhibits the growth of human colon cancer cells (SW480 cells) .
3-O-Methylquercetin tetraacetate is an antiplatelet agent. 3-O-Methylquercetin tetraacetate has potent antiplatelet effect on arachidonic acid, collagen-induced and PAF-induced platelet aggregation .
Kadsurenin C (compound 1) is a neolignan that can be isolated from the aerial part of Piper kadsura with anti-inflammation activity. Kadsurenin C exhibits significant PAF (Platelet ActivatingFactor)
antagonistic activity with IC50 value of 5.1 μM .
FR 106969 (A26771E) is a platelet activatingfactor antagonist with anti-inflammatory activity. FR 106969 can be used to alleviate inflammatory responses. FR 106969 has shown potential inhibitory effects on inflammation-related diseases in studies .
Aschantin, a bisepoxylignan, can be isolated from Magnolia biondii. Aschantin has antiplasmodial, Ca 2+-antagonistic, platelet activatingfactor-antagonistic, and chemopreventive activities. Aschantin is a mTOR kinase inhibitor. Aschantin is also an inhibitor of Cytochrome P450 and UGT enzyme .
Ginkgolide B (BN-52021), a terpene lactone, is a potent platelet activatingfactor antagonist. Ginkgolide B protects endothelial cells via the activation of PXR from injuries induced by xeno- and endobiotics. Ginkgolide B can pass through the brain-blood barrier. Ginkgolide B has anti-oxidant, anti-inflammatory, anti-tumor, and anti-apoptotic activity. Ginkgolide B has marked neuroprotective effects against ischemia-induced impairments .
The PLA2G7 protein is a lipoprotein-associated calcium-independent phospholipase A2 that plays a key role in phospholipid catabolism during inflammation and oxidative stress responses.It acts at the lipid-water interface and hydrolyzes the ester bond of the fatty acyl group at the sn-2 position, with particular preference for short-chain fatty acyl groups.PLA2G7 Protein, Mouse (HEK293, His) is the recombinant mouse-derived PLA2G7 protein, expressed by HEK293 , with C-His, C-6*His labeled tag.
PAFAHB Proteinas, incorporating Alpha-2 adrenergic receptors, facilitates catecholamine-induced adenylate cyclase inhibition through G proteins. Notably, oxymetazoline ranks as the most potent agonist, followed by clonidine and antagonists with yohimbine exhibiting the highest inhibitory activity. This insight into agonist and antagonist effectiveness sheds light on the pharmacological modulation of Alpha-2 adrenergic receptors by ADRA2A-VLPs. PAFAHB Protein, Human (His) is the recombinant human-derived PAFAHB protein, expressed by E. coli , with C-6*His labeled tag. The total length of PAFAHB Protein, Human (His) is 228 a.a., with molecular weight of ~31.0 kDa.
PLA2G7 Protein is a lipoprotein-associated calcium-independent phospholipase A2 involved in phospholipid catabolism during inflammatory and oxidative stress responses. It is also a secreted enzyme that catalyzes the degradation of platelet-activating factor to biologically inactive products. PLA2G7 can hydrolyze phospholipids with long fatty acyl chains, only if they carry oxidized functional groups. PLA2G7 Protein, Human (HEK293, His) is the recombinant human-derived PLA2G7 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of PLA2G7 Protein, Human (HEK293, His) is 420 a.a., with molecular weight of ~57 kDa.
The PLA2G7 protein is a lipoprotein-associated calcium-independent phospholipase A2 that plays a key role in phospholipid catabolism during inflammation and oxidative stress responses.It acts at the lipid-water interface and hydrolyzes the ester bond of the fatty acyl group at the sn-2 position, with particular preference for short-chain fatty acyl groups.PLA2G7 Protein, Mouse (Baculovirus, N-His, C-Myc) is the recombinant mouse-derived PLA2G7 protein, expressed by Sf9 insect cells , with C-Myc, N-10*His labeled tag.
The PLA2G7 protein is a lipoprotein-associated calcium-independent phospholipase A2 that plays a key role in phospholipid catabolism during inflammation and oxidative stress responses.It acts at the lipid-water interface and hydrolyzes the ester bond of the fatty acyl group at the sn-2 position, with particular preference for short-chain fatty acyl groups.PLA2G7 Protein, Mouse (HEK293, N-His, C-Myc) is the recombinant mouse-derived PLA2G7 protein, expressed by HEK293 , with C-Myc, N-10*His labeled tag.
In vitro experiments have demonstrated that the sphingomyelin phosphodiesterase 2 (SMPD2) protein plays a key role in catalyzing the hydrolysis of sphingomyelin, leading to the formation of ceramide and phosphocholine. Furthermore, SMPD2 exhibits its enzymatic activity by hydrolyzing 1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine (hemolytic platelet-activating factor) in vivo. SMPD2 Protein, Human (Cell-Free, His) is the recombinant human-derived SMPD2 protein, expressed by E. coli Cell-free , with N-10*His labeled tag. The total length of SMPD2 Protein, Human (Cell-Free, His) is 423 a.a., with molecular weight of 49.1 kDa.
(7-Methoxy-2-oxo-2H-chromen-4-yl)-acetic acid-d3 is the deuterium labeled MCA[1]. MCA is a coumarin derivative. MCA quantitates platelet-activatingfactor by high-performance liquid chromatography with fluorescent detection. MCA can modify FRET peptide substrates for analyzing protease activities[2][3].
(7-Methoxy-2-oxo-2H-chromen-4-yl)-acetic acid-d6 is the deuterium labeled MCA[1]. MCA is a coumarin derivative. MCA quantitates platelet-activatingfactor by high-performance liquid chromatography with fluorescent detection. MCA can modify FRET peptide substrates for analyzing protease activities[2][3]. (7-Methoxy-2-oxo-2H-chromen-4-yl)-acetic acid-d6 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
(7-Methoxy-2-oxo-2H-chromen-4-yl)-acetic acid-d6 is the deuterium labeled MCA[1]. MCA is a coumarin derivative. MCA quantitates platelet-activatingfactor by high-performance liquid chromatography with fluorescent detection. MCA can modify FRET peptide substrates for analyzing protease activities[2][3]. (7-Methoxy-2-oxo-2H-chromen-4-yl)-acetic acid-d6 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
C18-PAF, octadecane PAF, is the ligand of platelet-activatingfactor and PAF G protein-coupled receptor (PAFR). C18-PAF has renovasodilator properties and antihypertensive lipid properties. C18-PAF increases renal blood flow and causes dose-dependent systemic hypotension .
Inquiry Online
Your information is safe with us. * Required Fields.
